Quick Answer
Decoy Therapeutics Inc. reported Cash and Equivalents of $10.71 million for fiscal year 2025.
Decoy Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $10.71M | +339.9% |
| 2024 | $2.43M | -58.7% |
| 2023 | $5.90M | -51.3% |
| 2022 | $12.11M | -58.6% |
| 2021 | $29.21M | +162.8% |
| 2020 | $11.12M | +197.4% |
| 2019 | $3.74M | +15.8% |
| 2018 | $3.23M | -83.2% |
| 2017 | $19.19M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.81M | +46.5% | +505.1% |
| June 30, 2025 | $794.9K | -75.7% | -55.8% |
| March 31, 2025 | $1.80M | -58.9% | -26.1% |
| December 31, 2024 | $2.43M | -58.7% | -25.9% |
| September 30, 2024 | $3.28M | -56.7% | +0.3% |
| June 30, 2024 | $3.27M | -71.6% | -25.2% |
| March 31, 2024 | $4.37M | -52.8% | -25.9% |
| December 31, 2023 | $5.90M | -51.3% | -22.2% |
- Decoy Therapeutics Inc. showed an increase of +339.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Decoy Therapeutics Inc.’s cash and equivalents has declined by 44.2% (from $19.19 million to $10.71 million).
- The most recent figure is from Decoy Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: